Five Common Symptoms Of Stomach Cancer That Should Not Be Ignored

Updated Dec 13, 2024 | 02:53 PM IST

SummaryStomach or gastric cancer is a type of cancer that develops in the lining of the stomach. There are certain symptoms like vomiting blood, abdominal pain that should immediately be addressed.
Stomach cancer

Stomach cancer (credit: canva)

Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).

A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:

1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.

2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.

3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.

4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.

5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding

There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.

How Does Stomach Cancer Spread?

Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.

1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.

2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.

3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.

He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.

End of Article

'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Updated Nov 17, 2026 | 11:08 AM IST

SummaryDeveloped by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression including memory, thinking, and everyday functioning by the equivalent of 3.5 months over one year.
'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Credit: iStock

A new once-daily experimental pill slowed the decline in memory, thinking, and everyday functioning by 31% in some people with Alzheimer's disease in a Phase 3 trial.

Developed by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression by the equivalent of 3.5 months over one year.

Unlike existing dementia drugs, which primarily alleviate symptoms, AR1001 has shown potential to slow disease progression.

However, the benefit was significant only among patients who were not taking other dementia medications.

The company announced that "the trial had met its primary endpoint" at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, US.

What Did The Phase 3 Trial Find?

Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For

The global trial involved 1,535 people with Alzheimer's disease across 230 sites in 13 countries.

Researchers assessed participants using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, judgment and the ability to perform everyday activities.

The findings showed:

  • 31% slower decline: Among 604 patients taking AR1001 without other dementia medications, disease progression was 31% slower than in the placebo group.
  • 3.5-month delay: The difference was equivalent to delaying disease progression by approximately 3.5 months over one year.
  • No significant benefit in the overall group: Among all 1,535 participants, the benefit was 7% and was not statistically significant.

The findings suggest that AR1001's effectiveness may depend on whether patients are taking other Alzheimer's medications.

Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, described the results as encouraging.

"These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms," Dr Richard said, the Daily Mail reported.

"Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third," he added.

Why Is AR1001 Being Called 'Viagra For The Brain'?

Read More: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

AR1001 works differently from existing Alzheimer's treatments, such as lecanemab and donanemab, which target amyloid plaques in the brain.

Its active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, the compound used in Viagra to treat erectile dysfunction.

Both drugs inhibit an enzyme called phosphodiesterase-5 (PDE5). This helps relax blood vessels and improve blood flow.

Researchers believe AR1001 may have several effects in the brain, including:

  • Improving blood flow.
  • Reducing inflammation.
  • Protecting nerve cells.
  • Supporting cellular processes involved in brain function.

Unlike some existing disease-modifying treatments that require infusions or injections, AR1001 is designed as a once-daily oral medication.

However, the drug is from the same family of medicines as Viagra and is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.

Are there Any Side Effects?

Most side effects reported during the trial were mild to moderate. Common side effects included diarrhoea, falls and dizziness.

Severe adverse events occurred in 10% of the treatment group and 9.8% of the placebo group.

Researchers also reported changes in biomarkers associated with Alzheimer's disease. Levels of the protein p-tau217 decreased in the monotherapy group, while cerebrospinal fluid cGMP levels increased in both treatment groups.

These findings offer clues about the drug's biological activity, although further research is needed to establish its effects.

However, the lack of a statistically significant benefit among people taking other Alzheimer's medications, adding that this required further investigation.

AR1001 is not yet available to the public and must undergo regulatory assessment before it can be prescribed.

Regulatory approval will depend on further evaluation, including whether the FDA considers the monotherapy results sufficient to support the drug's approval.

End of Article

L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Updated Nov 17, 2026 | 09:27 AM IST

SummaryL'Oréal USA and several of its subsidiaries recently settled lawsuits related to their chemical hair relaxers and cancer risk in a trial held in Chicago,
L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Credit: AI-generated image

L'Oréal USA and other manufacturers of chemical hair relaxers have reached a settlement with four women who alleged that years of using hair straightening products contributed to their gynaecological cancers.

The settlement was made during the first US trial involving these claims, bringing newfound attention to research examining the health risks of chemical hair treatments.

What Do We Know About The L'Oréal's US Lawsuit?

According to Reuters, the four women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, settled their lawsuits for an undisclosed amount. The trial was being held in Chicago.

The women had sued L'Oréal's US subsidiary and several other manufacturers in 2023 and 2024, alleging that prolonged exposure to chemical hair straighteners caused their cancers.

The settlement comes as litigation involving these products continues to surface. More than 12,700 related cases have been consolidated before a federal judge in Chicago.

The products, sold under brand names including Dark and Lovely and Optimum, have been widely marketed to Black women.

Also read: What Is Viral Heightmaxxing? US Doctors Warn Teen Boys Against Taking Cancer Drug To Grow Taller

L'Oréal's Statement

L'Oréal has maintained that its products are safe. A company spokesperson said, "L’Oréal USA strictly follows all regulations in every market in which it operates and its products are always subject to a rigorous scientific evaluation of their safety."

The company has also argued that existing research does not establish that its products caused the conditions alleged in the lawsuits.

What Does Research Say About Hair Relaxers And Cancer?

Scientific interest in the health effects of chemical hair straighteners increased after a 2022 study by researchers at the US National Institutes of Health (NIH).

Published in the Journal of the National Cancer Institute, the study examined data from 33,497 women aged 35-74 participating in the Sister Study.

Over an average follow-up of nearly 11 years, 378 cases of uterine cancer were identified.

Researchers found that women who reported using chemical hair straightening products more than four times in the preceding year had more than twice the risk of developing uterine cancer compared to women who had never used them.

The study estimated that 1.64% of women who had never used hair straighteners would develop uterine cancer by age 70, compared to 4.05% among frequent users.

However, researchers did not focus on the specific brands or chemical ingredients used, meaning they could not identify which substances might have contributed to the observed association.

Also read: Can A 'Sponge On A String' Test Help Detect Oesophageal Cancer Before Symptoms?

High Risk Of Breast And Ovarian Cancer

Other studies have also investigated links between chemical hair treatments and reproductive cancers.

A 2021 study published in Carcinogenesis found that frequent use of hair straighteners and relaxers may cause an increased risk of ovarian cancer. Women who used these products more than four times a year had approximately twice the risk compared with non-users.

Research from the Sister Study cohort has also showed an increased risk of breast cancer due to frequent hair straightener use especially among women who used the products regularly.

However, the findings are not the same across all studies. A 2025 systematic review examining evidence among Black women in the US concluded that the epidemiological evidence that is available did not support an increased risk of breast, ovarian or uterine cancers due to hair relaxer use.

Are Chemicals In Hair Straighteners Dangerous For Health?

Chemical hair relaxers and straighteners contain different substances depending on their formulation. Some products may contain endocrine-disrupting chemicals, including phthalates and parabens, which can interfere with hormonal activity.

Other concerning chemicals include formaldehyde and certain preservatives. Some straightening treatments can release formaldehyde, a recognised carcinogen.

Researchers have suggested that exposure to endocrine-disrupting chemicals could affect hormonal tissues.

End of Article

Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Updated Nov 17, 2026 | 08:46 AM IST

SummaryThe European Commission granted marketing authorisation to Revolution Medicines to produce and sell RASONQUE (daraxonrasib) to treat aggressive metastatic pancreatic adenocarcinoma.
Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Credit: AI-generated image

The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.

The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.

RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.

The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.

More About RASONQUE

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.

Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.

Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.

Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.

Also read: Bowel, Pancreatic & Liver: NHS Trial Offers New Blood Test To 20,000 Patients That Could Detect 13 Cancers

What Did The Clinical Trial Find?

The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.

According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.

Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.

The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.

Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients

What Are The Side Effects?

The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.

The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.

Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.

Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.

The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.

End of Article